Lay­offs hit an­oth­er biotech as Duchenne play­er Sol­id Bio cuts staff by 35%

An­oth­er biotech has joined the ranks of the re­or­ga­nized, as Duchenne play­er Sol­id Bio­sciences re­port­ed a new way of do­ing things Wednes­day and an­nounced lay­offs and a C-suite de­par­ture.

Sol­id Bio is re­duc­ing its work­force by 35%, ac­cord­ing to an SEC fil­ing for its first-quar­ter re­sults Wednes­day, in ad­di­tion to a new em­pha­sis on its two gene ther­a­pies. The pipeline shift in­cludes an out­sourced man­u­fac­tur­ing process rather than what was used pre­vi­ous­ly, al­low­ing for a more stream­lined de­vel­op­ment process, the com­pa­ny said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER